Hutchmed

This study tests whether adding two extra drugs (surufatinib and camrelizumab) to standard chemotherapy can help people with metastatic pancreatic cancer live longer and control their disease better. About 500 adults aged 18-75 who have not had prior treatment for their advanced …

This early-phase study tests a new drug called HMPL-A580 in adults with advanced or metastatic solid tumors that cannot be removed by surgery. The main goals are to find a safe dose and see if the drug can shrink tumors. About 186 participants will take part in this first-in-huma…

This study tests a new drug called HMPL-A251 in adults with advanced or spreading solid tumors that have a protein called HER2. The goal is to find a safe dose and see if the drug can shrink tumors. About 147 participants will receive the drug, and researchers will monitor side e…

This study tests an experimental drug, HMPL-453, in adults with advanced bile duct cancer that has a specific change in the FGFR2 gene. The drug is taken as a pill for 14 days, then a week off. The main goal is to see if it shrinks tumors. About 235 people will join.

This early-stage study tests an experimental pill called HMPL-506 in about 132 adults with certain blood cancers (like AML and ALL) that have come back or not responded to treatment. The main goals are to check the drug's safety, find the right dose, and see if it can shrink or c…

This study tests whether adding the experimental drug HMPL-760 to standard chemotherapy (R-GemOx) helps people with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) live longer without their cancer getting worse. About 240 adults who have already tried other treatment…